Claims for Patent: 8,759,372
✉ Email this page to a colleague
Summary for Patent: 8,759,372
Title: | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt |
Abstract: | Disclosed is a hemisulfate salt of Compound (I): ##STR00001## and crystalline forms of the hemisulfate salt. Also disclosed are methods of using the hemisulfate salt of Compound (I) as a CGRP receptor antagonist, and pharmaceutical compositions comprising the hemisulfate salt of Compound (I). The hemisulfate salt of Compound (I) is useful in treating, preventing, or ameliorating disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). |
Inventor(s): | Roberts; Daniel Richard (Robbinsville, NJ), Schartman; Richard Raymond (Wallingford, CT), Wei; Chenkou (Princeton Junction, NJ) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 13/775,528 |
Patent Claims: |
1. A hemisulfate salt of Compound (I): ##STR00012##
2. The hemisulfate salt of Compound (I) according to claim 1, wherein said salt of Compound (I) is crystalline. 3. The hemisulfate salt of Compound (I) according to claim 1, wherein said salt Compound (I) is a sesquihydrate. 4. The hemisulfate salt of Compound (I) according to claim 3, wherein said salt comprises crystalline Form H1.5-1. 5. The hemisulfate salt of Compound (I) according to claim 4, wherein said Form H1.5-1 is characterized by one or more of the following: a) unit cell parameters substantially equal to the following: Cell dimensions: a=10.92 .ANG. b=33.04 .ANG. c=7.90 .ANG. .alpha.=90 degrees .beta.=90 degrees .gamma.=90 degrees Space group: P2.sub.12.sub.12 Molecules of Compound (I)/asymmetric unit: I Volume=2851 .ANG..sup.3 Density (calculated)=1.423 g/cm.sup.3, wherein measurement of said crystalline form is at a temperature of about 25.degree. C.; b) an observed powder x-ray diffraction pattern substantially in accordance with the pattern shown in FIG. 1; c) a simulated powder x-ray diffraction pattern substantially in accordance with the pattern shown in FIG. 1; d) a powder x-ray diffraction pattern (CuK.alpha. .lamda.=1.5418 .ANG.) comprising four or more 2.theta. values selected from: 5.4.+-.0.1, 8.6.+-.0.1, 9.7.+-.0.1, 12.4.+-.0.1, 14.9.+-.0.1, 17.6.+-.0.1, 18.1.+-.0.1, 20.5.+-.0.1, 21.4.+-.0.1, and 22.0.+-.0.1, wherein measurement of the crystalline form is at a temperature of about 25.degree. C.; and/or e) a solid state nuclear resonance spectra comprising six or more peaks ((ppm) referenced to TMS) selected from: 26.6.+-.0.1, 27.1.+-.0.1, 28.3.+-.0.1, 30.7.+-.0.1, 43.1.+-.0.1, 45.9.+-.0.1, 47.1.+-.0.1, 52.0.+-.0.1, 54.2.+-.0.1, 72.5.+-.0.1, 117.0.+-.0.1, 117.7.+-.0.1, 124.2.+-.0.1, 125.2.+-.0.1, 128.3.+-.0.1, 130.3.+-.0.1, 131.4.+-.0.1, 134.1.+-.0.1, 140.8.+-.0.1, 144.7.+-.0.1, 148.7.+-.0.1, 149.8.+-.0.1, 151.2.+-.0.1, 153.4.+-.0.1, 155.1.+-.0.1, 155.6.+-.0.1, and 156.7.+-.0.1. 6. A pharmaceutical composition comprising said hemisulfate salt of Compound (I) according to claim 1; and a pharmaceutically acceptable carrier of diluent. 7. The pharmaceutical composition according to claim 6, wherein said hemisulfate salt of Compound (I) is a sesquihydrate. 8. The pharmaceutical composition according to claim 7, wherein said hemisulfate salt of Compound (I) comprises crystalline Form H1.5-1. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.